Jurek Kozyra Named CEO as Nanovery Enters Next Growth Phase

20 Jan 2025
Jurek Kozyra

As part of our ongoing growth and development programme, we are pleased to announce the appointment of Jurek Kozyra, Founder and Chief Business Officer, to the CEO role.

Mark Chadwick, the outgoing CEO, has guided the company through its transition from a research-led organisation to a commercially focused one and will transition to a role as Senior board advisor. We would like to thank Mark for his leadership and guidance as CEO, his continued commitment to the success of Nanovery, and his ongoing support of the board in his new role.

Comments from Mark:

I am today announcing my transition from part time CEO of Nanovery to Senior Board Advisor. As a company, we have made amazing strides in refocusing our Nanorobot platform towards the RNA therapeutics market, including 2 top 10 pharma breakthrough deals and with further projects imminent. However, in a challenging investment environment, I feel this is the way I can continue to best support the company through its next funding round and phase of development. I will always champion the amazing team at Nanovery, who have become very much friends as well as colleagues. I feel sure that they will all continue onwards with courage and fortitude, and achieve great things together!

Comments from Jurek:

The past two years have been an incredible journey of learning and growth for Nanovery. We took bold steps to bring our technology to the forefront, achieving first commercial deals and seeing uptake from leading pharma and biotech companies. These milestones reflect our team's dedication and hard work as we expanded our capabilities and refined our focus. As Chief Business Officer, I had the privilege of working closely with our partners and customers to demonstrate the potential of Nanovery’s platform. Stepping up into the CEO role, I’m excited to continue driving this mission forward as we enter a new phase of growth.

Read also

We are a data driven company using DNA nanotechnology and AI to scale up testing of nucleic acids for powerful insights from valuable samples.